|
US2913451A
(en)
*
|
1957-04-04 |
1959-11-17 |
Mallinckrodt Chemical Works |
Iodophenylamidoalkanesulfonic acid compounds
|
|
US5700444A
(en)
*
|
1992-02-20 |
1997-12-23 |
Rhomed Incorporated |
Chemotactic peptide pharmaceutical applications
|
|
US5759515A
(en)
*
|
1989-08-09 |
1998-06-02 |
Rhomed Incorporated |
Polyvalent peptide pharmaceutical applications
|
|
US5469854A
(en)
|
1989-12-22 |
1995-11-28 |
Imarx Pharmaceutical Corp. |
Methods of preparing gas-filled liposomes
|
|
US5305757A
(en)
*
|
1989-12-22 |
1994-04-26 |
Unger Evan C |
Gas filled liposomes and their use as ultrasonic contrast agents
|
|
US6146657A
(en)
*
|
1989-12-22 |
2000-11-14 |
Imarx Pharmaceutical Corp. |
Gas-filled lipid spheres for use in diagnostic and therapeutic applications
|
|
US5585112A
(en)
*
|
1989-12-22 |
1996-12-17 |
Imarx Pharmaceutical Corp. |
Method of preparing gas and gaseous precursor-filled microspheres
|
|
US5773024A
(en)
*
|
1989-12-22 |
1998-06-30 |
Imarx Pharmaceutical Corp. |
Container with multi-phase composition for use in diagnostic and therapeutic applications
|
|
OA10149A
(en)
*
|
1991-03-29 |
1996-12-18 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists
|
|
US20020032313A1
(en)
|
1991-03-29 |
2002-03-14 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
|
US5205290A
(en)
|
1991-04-05 |
1993-04-27 |
Unger Evan C |
Low density microspheres and their use as contrast agents for computed tomography
|
|
US5861301A
(en)
*
|
1992-02-20 |
1999-01-19 |
American Cayanamid Company |
Recombinant kinase insert domain containing receptor and gene encoding same
|
|
US5965132A
(en)
*
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
EP0627940B1
(en)
|
1992-03-05 |
2003-05-07 |
Board of Regents, The University of Texas System |
Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors
|
|
WO1993022343A1
(en)
*
|
1992-05-01 |
1993-11-11 |
The Rockfeller University |
Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
|
|
US6824777B1
(en)
*
|
1992-10-09 |
2004-11-30 |
Licentia Ltd. |
Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
|
|
AU687727B2
(en)
|
1992-10-28 |
1998-03-05 |
Genentech Inc. |
Vascular endothelial cell growth factor antagonists
|
|
EP0751992B1
(en)
*
|
1994-03-08 |
2005-11-09 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
|
US6245530B1
(en)
*
|
1995-08-01 |
2001-06-12 |
Ludwig Institute For Cancer Research |
Receptor ligand
|
|
US6221839B1
(en)
*
|
1994-11-14 |
2001-04-24 |
Helsinki University Licensing Ltd. Oy |
FIt4 ligand and methods of use
|
|
US6645933B1
(en)
*
|
1995-08-01 |
2003-11-11 |
Helsinki University Licensing Ltd. Oy |
Receptor ligand VEGF-C
|
|
US6130071A
(en)
*
|
1997-02-05 |
2000-10-10 |
Helsinki University Licensing, Ltd. |
Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
|
|
US6403088B1
(en)
*
|
1995-08-01 |
2002-06-11 |
Helsinki University Licensing, Ltd. |
Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
|
|
US6033645A
(en)
*
|
1996-06-19 |
2000-03-07 |
Unger; Evan C. |
Methods for diagnostic imaging by regulating the administration rate of a contrast agent
|
|
US6231834B1
(en)
*
|
1995-06-07 |
2001-05-15 |
Imarx Pharmaceutical Corp. |
Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
|
|
US6521211B1
(en)
*
|
1995-06-07 |
2003-02-18 |
Bristol-Myers Squibb Medical Imaging, Inc. |
Methods of imaging and treatment with targeted compositions
|
|
CA2218541A1
(en)
|
1995-06-07 |
1996-12-19 |
Imarx Pharmaceutical Corp. |
Novel targeted compositions for diagnostic and therapeutic use
|
|
US7423125B2
(en)
*
|
1995-08-01 |
2008-09-09 |
Vegenics Limited |
Antibodies to VEGF-C
|
|
US6361946B1
(en)
*
|
1997-02-05 |
2002-03-26 |
Licentia Ltd |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
|
ES2202469T5
(es)
*
|
1995-09-08 |
2011-06-06 |
Genentech, Inc. |
Proteína relacionada con el vegf.
|
|
US6331289B1
(en)
*
|
1996-10-28 |
2001-12-18 |
Nycomed Imaging As |
Targeted diagnostic/therapeutic agents having more than one different vectors
|
|
GB9708265D0
(en)
*
|
1997-04-24 |
1997-06-18 |
Nycomed Imaging As |
Contrast agents
|
|
BR9713978A
(pt)
|
1996-10-28 |
2000-05-02 |
Nycomed Imaging As |
Agente diagnóstico alvejável e/ou terapeuticamente ativo, processo para preparação e uso do mesmo, formulação combinada, e, processos para gerar imagens intensificadas de um corpo animal humano ou não-humano e para investigação in vitro de alvejamento por um agente
|
|
BR9712683A
(pt)
*
|
1996-10-28 |
1999-10-19 |
Nyomed Imaging A S |
Agente de diagnóstico e/ou terapeuticamente ativo alvejável, formulação combinada, processo para preparação e uso do mesmo, formulação combinada, e processos para gerar imagens intensificadas de um corpo animal humano ou não-humano e para investigação in vitro de alvejamento por um agente.
|
|
US6261537B1
(en)
*
|
1996-10-28 |
2001-07-17 |
Nycomed Imaging As |
Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
|
|
US7125714B2
(en)
*
|
1997-02-05 |
2006-10-24 |
Licentia Ltd. |
Progenitor cell materials and methods
|
|
US20020010137A1
(en)
*
|
1997-09-18 |
2002-01-24 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
|
US6245318B1
(en)
*
|
1997-05-27 |
2001-06-12 |
Mallinckrodt Inc. |
Selectively binding ultrasound contrast agents
|
|
WO1998058053A1
(en)
*
|
1997-06-18 |
1998-12-23 |
Merck & Co., Inc. |
Human receptor tyrosine kinase, kdr
|
|
US6777534B1
(en)
*
|
1997-12-09 |
2004-08-17 |
Children's Medical Center Corporation |
Peptide antagonists of vascular endothelial growth factor
|
|
IL138214A0
(en)
*
|
1998-03-09 |
2001-10-31 |
Zealand Pharmaceuticals As |
Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
US6524553B2
(en)
*
|
1998-03-31 |
2003-02-25 |
Bristol-Myers Squibb Pharma Company |
Quinolone vitronectin receptor antagonist pharmaceuticals
|
|
KR20010042288A
(ko)
*
|
1998-03-31 |
2001-05-25 |
블레어 큐. 퍼거슨 |
신생혈관 형성 질환의 영상화용 약제
|
|
US6537520B1
(en)
*
|
1998-03-31 |
2003-03-25 |
Bristol-Myers Squibb Pharma Company |
Pharmaceuticals for the imaging of angiogenic disorders
|
|
US6548663B1
(en)
*
|
1998-03-31 |
2003-04-15 |
Bristol-Myers Squibb Pharma Company |
Benzodiazepine vitronectin receptor antagonist pharmaceuticals
|
|
US6548048B1
(en)
*
|
1998-04-28 |
2003-04-15 |
Amersham Health As |
Lipopeptide stabilized microbubbles as diagnostic/therapeutic agents
|
|
US7173005B2
(en)
*
|
1998-09-02 |
2007-02-06 |
Antyra Inc. |
Insulin and IGF-1 receptor agonists and antagonists
|
|
US6875741B2
(en)
*
|
1998-09-02 |
2005-04-05 |
Renuka Pillutla |
Insulin and IGF-1 receptor agonists and antagonists
|
|
US20030236190A1
(en)
*
|
1998-09-02 |
2003-12-25 |
Renuka Pillutla |
Isulin and IGF-1 receptor agonists and antagonists
|
|
DE19941092A1
(de)
|
1999-08-30 |
2001-03-01 |
Philips Corp Intellectual Pty |
Netzwerk mit einer Kennungsreduktion
|
|
EP1248642A4
(en)
*
|
2000-01-18 |
2005-05-18 |
Ludwig Inst Cancer Res |
PEPTIDOMIMETIC INHIBITOR OF VEGF-D / VEGF-C / VEGF
|
|
US7740841B1
(en)
*
|
2000-01-28 |
2010-06-22 |
Sunnybrook Health Science Center |
Therapeutic method for reducing angiogenesis
|
|
WO2001057067A1
(en)
*
|
2000-02-04 |
2001-08-09 |
Supratek Pharma Inc. |
Ligand for vascular endothelial growth factor receptor
|
|
ATE284701T1
(de)
|
2000-03-02 |
2005-01-15 |
Ludwig Inst Cancer Res |
Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
|
|
DK1259248T3
(da)
|
2000-03-02 |
2005-04-11 |
Ludwig Inst Cancer Res |
Fremgangsmåde til behandling af cancere, der udtrykker vaskulær endotelvækstfaktor D
|
|
US20020102260A1
(en)
*
|
2000-03-02 |
2002-08-01 |
Marc Achen |
Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
|
|
US20010031485A1
(en)
*
|
2000-03-22 |
2001-10-18 |
Sibtech, Inc. |
Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
|
|
WO2001072829A2
(en)
*
|
2000-03-31 |
2001-10-04 |
Institut Pasteur |
Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
|
|
JP2004501091A
(ja)
*
|
2000-05-03 |
2004-01-15 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
血管内皮成長因子レセプタ−３のみを活性化する方法とその利用法
|
|
EP1166799A1
(en)
|
2000-06-28 |
2002-01-02 |
Schering Aktiengesellschaft |
Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II)
|
|
DK1292335T3
(da)
*
|
2000-06-23 |
2007-09-17 |
Bayer Schering Pharma Ag |
Kombinationer og sammensætninger, som interfererer med VEGF/VEGF og angiopoietin/Tie receptor funktion og deres anvendelse (II)
|
|
EP1166798A1
(en)
|
2000-06-23 |
2002-01-02 |
Schering Aktiengesellschaft |
Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use
|
|
AU2001276934A1
(en)
*
|
2000-07-18 |
2002-02-05 |
Joslin Diabetes Center Inc. |
Methods of modulating fibrosis
|
|
US20020091082A1
(en)
*
|
2000-09-13 |
2002-07-11 |
Aiello Lloyd P. |
Methods of modulating symptoms of hypertension
|
|
US20030082103A1
(en)
*
|
2000-10-11 |
2003-05-01 |
Targesome, Inc. |
Targeted therapeutic lipid constructs having cell surface targets
|
|
US20020091567A1
(en)
*
|
2001-01-09 |
2002-07-11 |
Royston Tymarshall E. |
System and method for electronically redeeming coupons
|
|
US7611711B2
(en)
*
|
2001-01-17 |
2009-11-03 |
Vegenics Limited |
VEGFR-3 inhibitor materials and methods
|
|
JP2004525916A
(ja)
*
|
2001-03-08 |
2004-08-26 |
ターゲサム・インコーポレーテッド |
安定化された治療剤および撮像剤
|
|
AU2002252631A1
(en)
*
|
2001-04-13 |
2002-10-28 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
|
US7056679B2
(en)
*
|
2001-10-24 |
2006-06-06 |
Antyra, Inc. |
Target specific screening and its use for identifying target binders
|
|
AU2003228276B8
(en)
*
|
2002-03-01 |
2010-02-18 |
Bracco Suisse S.A. |
Multivalent constructs for therapeutic and diagnostic applications
|
|
US7211240B2
(en)
|
2002-03-01 |
2007-05-01 |
Bracco International B.V. |
Multivalent constructs for therapeutic and diagnostic applications
|
|
US20050100963A1
(en)
|
2002-03-01 |
2005-05-12 |
Dyax Corporation |
KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
|
|
ES2398393T3
(es)
*
|
2002-03-01 |
2013-03-15 |
Dyax Corp. |
Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia
|
|
EP1501357A4
(en)
*
|
2002-05-06 |
2009-10-21 |
Genentech Inc |
USE OF VEGF FOR THE TREATMENT OF BONE DEFECTS
|
|
US20040212193A1
(en)
|
2002-10-08 |
2004-10-28 |
Johnstone Ian David |
Connector
|
|
NO20026286D0
(no)
*
|
2002-12-30 |
2002-12-30 |
Amersham Health As |
Nye peptider
|
|
NO20026285D0
(no)
|
2002-12-30 |
2002-12-30 |
Amersham Health As |
Nye peptider
|
|
WO2004085617A2
(en)
|
2003-03-21 |
2004-10-07 |
The Cleveland Clinic Foundation |
Timp3 as vegf inhibitor
|
|
US7601341B2
(en)
*
|
2003-06-05 |
2009-10-13 |
Research Development Foundation |
Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
|
|
US20050032697A1
(en)
|
2003-06-12 |
2005-02-10 |
Kari Alitalo |
Heparin binding VEGFR-3 ligands
|
|
US20050043235A1
(en)
|
2003-06-12 |
2005-02-24 |
Kari Alitalo |
Use of VEGF-C or VEGF-D in reconstructive surgery
|
|
JP2005110508A
(ja)
|
2003-10-02 |
2005-04-28 |
Nec Soft Ltd |
血管内皮増殖因子受容体２型に対する特異的結合性を有するヘビ毒由来血管内皮増殖因子様タンパク質と用途
|
|
DE602005021057D1
(de)
|
2004-01-20 |
2010-06-17 |
Toronto E |
Hochfrequenz-ultraschall-darstellung mit kontrastmitteln
|
|
WO2005072417A2
(en)
|
2004-01-27 |
2005-08-11 |
The Ohio State University Research Foundation |
Vascular endothelial growth factors and methods of their use
|
|
JP2008509157A
(ja)
|
2004-08-06 |
2008-03-27 |
ソフェリオン セラピューティクス，インコーポレイテッド |
抗血管新生ペプチドおよびその使用方法
|